# Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

> **NCT03924245** · PHASE1 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Fallopian Tube Carcinosarcoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- High Grade Fallopian Tube Serous Adenocarcinoma
- High Grade Ovarian Serous Adenocarcinoma
- Ovarian Carcinosarcoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Recurrent Endometrial Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03924245
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-01
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-02-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Change in participant landscape and other treatment availability
- **Last updated:** 2022-04-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03924245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03924245, "Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03924245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*